274 related articles for article (PubMed ID: 32324594)
1. CCL5 mediates CD40-driven CD4+ T cell tumor infiltration and immunity.
Huffman AP; Lin JH; Kim SI; Byrne KT; Vonderheide RH
JCI Insight; 2020 May; 5(10):. PubMed ID: 32324594
[TBL] [Abstract][Full Text] [Related]
2. CD4+ T cells elicit host immune responses to MHC class II-negative ovarian cancer through CCL5 secretion and CD40-mediated licensing of dendritic cells.
Nesbeth YC; Martinez DG; Toraya S; Scarlett UK; Cubillos-Ruiz JR; Rutkowski MR; Conejo-Garcia JR
J Immunol; 2010 May; 184(10):5654-62. PubMed ID: 20400704
[TBL] [Abstract][Full Text] [Related]
3. Successful immunotherapy with IL-2/anti-CD40 induces the chemokine-mediated mitigation of an immunosuppressive tumor microenvironment.
Weiss JM; Back TC; Scarzello AJ; Subleski JJ; Hall VL; Stauffer JK; Chen X; Micic D; Alderson K; Murphy WJ; Wiltrout RH
Proc Natl Acad Sci U S A; 2009 Nov; 106(46):19455-60. PubMed ID: 19892741
[TBL] [Abstract][Full Text] [Related]
4. Intratumoral interleukin-2/agonist CD40 antibody drives CD4+ -independent resolution of treated-tumors and CD4+ -dependent systemic and memory responses.
Jackaman C; Nelson DJ
Cancer Immunol Immunother; 2012 Apr; 61(4):549-60. PubMed ID: 22002241
[TBL] [Abstract][Full Text] [Related]
5. Infiltrating CD4+ T cells attenuate chemotherapy sensitivity in prostate cancer via CCL5 signaling.
Xiang P; Jin S; Yang Y; Sheng J; He Q; Song Y; Yu W; Hu S; Jin J
Prostate; 2019 Jun; 79(9):1018-1031. PubMed ID: 31018021
[TBL] [Abstract][Full Text] [Related]
6. Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors.
Nowak AK; Robinson BW; Lake RA
Cancer Res; 2003 Aug; 63(15):4490-6. PubMed ID: 12907622
[TBL] [Abstract][Full Text] [Related]
7. Cooperation between Constitutive and Inducible Chemokines Enables T Cell Engraftment and Immune Attack in Solid Tumors.
Dangaj D; Bruand M; Grimm AJ; Ronet C; Barras D; Duttagupta PA; Lanitis E; Duraiswamy J; Tanyi JL; Benencia F; Conejo-Garcia J; Ramay HR; Montone KT; Powell DJ; Gimotty PA; Facciabene A; Jackson DG; Weber JS; Rodig SJ; Hodi SF; Kandalaft LE; Irving M; Zhang L; Foukas P; Rusakiewicz S; Delorenzi M; Coukos G
Cancer Cell; 2019 Jun; 35(6):885-900.e10. PubMed ID: 31185212
[TBL] [Abstract][Full Text] [Related]
8. CD40 and CD70 co-stimulate a potent in vivo antitumor T cell response.
Nieland JD; Graus YF; Dortmans YE; Kremers BL; Kruisbeek AM
J Immunother; 1998 May; 21(3):225-36. PubMed ID: 9610915
[TBL] [Abstract][Full Text] [Related]
9. Tumor-derived chemokine CCL5 enhances TGF-β-mediated killing of CD8(+) T cells in colon cancer by T-regulatory cells.
Chang LY; Lin YC; Mahalingam J; Huang CT; Chen TW; Kang CW; Peng HM; Chu YY; Chiang JM; Dutta A; Day YJ; Chen TC; Yeh CT; Lin CY
Cancer Res; 2012 Mar; 72(5):1092-102. PubMed ID: 22282655
[TBL] [Abstract][Full Text] [Related]
10. CD27 Agonism Plus PD-1 Blockade Recapitulates CD4+ T-cell Help in Therapeutic Anticancer Vaccination.
Ahrends T; Bąbała N; Xiao Y; Yagita H; van Eenennaam H; Borst J
Cancer Res; 2016 May; 76(10):2921-31. PubMed ID: 27020860
[TBL] [Abstract][Full Text] [Related]
11. Treatment-enhanced CD4+Foxp3+ glucocorticoid-induced TNF receptor family related high regulatory tumor-infiltrating T cells limit the effectiveness of cytokine-based immunotherapy.
Berhanu A; Huang J; Watkins SC; Okada H; Storkus WJ
J Immunol; 2007 Mar; 178(6):3400-8. PubMed ID: 17339434
[TBL] [Abstract][Full Text] [Related]
12. TRANCE, a tumor necrosis factor family member critical for CD40 ligand-independent T helper cell activation.
Bachmann MF; Wong BR; Josien R; Steinman RM; Oxenius A; Choi Y
J Exp Med; 1999 Apr; 189(7):1025-31. PubMed ID: 10190893
[TBL] [Abstract][Full Text] [Related]
13. Radiotherapy and CD40 Activation Separately Augment Immunity to Checkpoint Blockade in Cancer.
Rech AJ; Dada H; Kotzin JJ; Henao-Mejia J; Minn AJ; Twyman-Saint Victor C; Vonderheide RH
Cancer Res; 2018 Aug; 78(15):4282-4291. PubMed ID: 29844122
[TBL] [Abstract][Full Text] [Related]
14. 4-1BB-specific monoclonal antibody promotes the generation of tumor-specific immune responses by direct activation of CD8 T cells in a CD40-dependent manner.
Miller RE; Jones J; Le T; Whitmore J; Boiani N; Gliniak B; Lynch DH
J Immunol; 2002 Aug; 169(4):1792-800. PubMed ID: 12165501
[TBL] [Abstract][Full Text] [Related]
15. Tumor regression induced by intratumor administration of adenovirus vector expressing CD40 ligand and naive dendritic cells.
Kikuchi T; Miyazawa N; Moore MA; Crystal RG
Cancer Res; 2000 Nov; 60(22):6391-5. PubMed ID: 11103803
[TBL] [Abstract][Full Text] [Related]
16. CCL5-deficiency enhances intratumoral infiltration of CD8
Zhang S; Zhong M; Wang C; Xu Y; Gao WQ; Zhang Y
Cell Death Dis; 2018 Jul; 9(7):766. PubMed ID: 29991744
[TBL] [Abstract][Full Text] [Related]
17. CDK4/6 inhibition promotes immune infiltration in ovarian cancer and synergizes with PD-1 blockade in a B cell-dependent manner.
Zhang QF; Li J; Jiang K; Wang R; Ge JL; Yang H; Liu SJ; Jia LT; Wang L; Chen BL
Theranostics; 2020; 10(23):10619-10633. PubMed ID: 32929370
[TBL] [Abstract][Full Text] [Related]
18. Combination of radiotherapy and vaccination overcomes checkpoint blockade resistance.
Zheng W; Skowron KB; Namm JP; Burnette B; Fernandez C; Arina A; Liang H; Spiotto MT; Posner MC; Fu YX; Weichselbaum RR
Oncotarget; 2016 Jul; 7(28):43039-43051. PubMed ID: 27343548
[TBL] [Abstract][Full Text] [Related]
19. CD40 ligand promotes priming of fully potent antitumor CD4(+) T cells in draining lymph nodes in the presence of apoptotic tumor cells.
Fujita N; Kagamu H; Yoshizawa H; Itoh K; Kuriyama H; Matsumoto N; Ishiguro T; Tanaka J; Suzuki E; Hamada H; Gejyo F
J Immunol; 2001 Nov; 167(10):5678-88. PubMed ID: 11698440
[TBL] [Abstract][Full Text] [Related]
20. CD4+ T cells induce rejection of urothelial tumors after immune checkpoint blockade.
Sato Y; Bolzenius JK; Eteleeb AM; Su X; Maher CA; Sehn JK; Arora VK
JCI Insight; 2018 Dec; 3(23):. PubMed ID: 30518683
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
